Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;54(8):773-780.
doi: 10.1111/hepr.14024. Epub 2024 Feb 14.

Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma

Nobuaki Ishihara  1 , Shohei Komatsu  1 , Keitaro Sofue  2 , Eisuke Ueshima  2 , Yoshihiko Yano  3 , Yoshimi Fujishima  4 , Jun Ishida  5 , Masahiro Kido  1 , Hidetoshi Gon  1 , Kenji Fukushima  1 , Takeshi Urade  1 , Hiroaki Yanagimoto  1 , Hirochika Toyama  1 , Yoshihide Ueda  3 , Yuzo Kodama  3 , Takamichi Murakami  2 , Takumi Fukumoto  1
Affiliations

Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma

Nobuaki Ishihara et al. Hepatol Res. 2024 Aug.

Abstract

Aim: The IMbrave150 trial revealed that atezolizumab plus bevacizumab (AtezoBv) showed a higher objective response rate (ORR) in patients with advanced hepatocellular carcinoma (HCC). Although conversion therapy after AtezoBv has been recently reported, markers predictive of its efficacy, particularly radiological imaging markers, have not yet been identified. The present study focused on tumor morphological appearance on radiological imaging and evaluated whether it could be associated with AtezoBv efficacy.

Methods: Ninety-five intrahepatic lesions in 74 patients who were given AtezoBv for advanced HCC were recruited for evaluation. The lesions were divided into two groups, simple nodular (SN group) and non-simple nodular (non-SN group), based on the gross morphology on pretreatment imaging, and retrospectively evaluated for treatment response and other relevant clinical outcomes.

Results: Assessing the size of individual tumors after treatment, waterfall plots showed that tumor shrinkage in the non-SN group including 56 lesions was higher than that in the SN group comprising 39 lesions. The ORR was significantly higher in the non-SN group (39.3% vs. 15.4%, p = 0.012). Additionally, the median time to nodular progression was longer in the non-SN group (21.0 months vs. 8.1 months, p = 0.119) compared to the SN group. Six patients with non-SN lesions underwent sequential local therapy.

Conclusions: Atezolizumab plus bevacizumab may show increased therapeutic efficacy in patients with tumors with a higher potential for aggressive oncological behavior, such as non-SN lesions. Treatment strategies focusing on conversion therapy may be crucial in patients with non-SN lesions.

Keywords: atezolizumab plus bevacizumab; hepatocellular carcinoma; imaging biomarker.

PubMed Disclaimer

References

REFERENCES

    1. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7(1):6. https://doi.org/10.1038/s41572‐020‐00240‐3
    1. Reig M, Forner A, Rimola J, Ferrer‐Fàbrega J, Burrel M, Garcia‐Criado À, et al. BCLB strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–693.
    1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. https://doi.org/10.1056/nejmoa1915745
    1. Hidaka Y, Tomita M, Desaki R, Hamanoue M, Takao S, Kirishima M, et al. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report. World J Surg Oncol. 2022;20(1):228. https://doi.org/10.1186/s12957‐022‐02691‐2
    1. Miyata T, Sugi K, Horino T, Ono A, Tagayasu Y, Nomoto D, et al. Conversion surgery after atezolizumab plus bevacizumab for primary and peritoneal metastasis after hepatocellular carcinoma rupture. Anticancer Res. 2023;43(2):943–947. https://doi.org/10.21873/anticanres.16239

Grants and funding

LinkOut - more resources